江西省工业强省建设工作领导小组关于印发江西省支持医药产业高质量发展的若干措施的…

Country-interest evidence · pilot

Trade inferences use UN Comtrade, with China as reporter. Country connections indicate potential trade relevance, not measured harm, firm-level exposure or legal applicability. Inward measures concern exporters to China; competition with Chinese exports in third markets is not assessed.

Inspect implementing jurisdictions and partner evidence · 46 relationships

Argentina: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 42,419,077

Australia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 215,472,215

Austria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 399,904,647

Belgium: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 1,250,824,208

Bulgaria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 4,490,712

Brazil: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 31,805,587

Canada: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 548,115,825

Switzerland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 2,897,331,803

Cyprus: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 2,926,265

Czech Republic: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 1,415,915

Germany: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 7,403,150,465

Denmark: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 965,478,913

Spain: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 658,310,865

Finland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 119,997,547

France: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 3,202,265,000

United Kingdom: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 884,758,236

Greece: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 242,780,544

Hong Kong, China: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 626,768,104

Hungary: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 67,058,023

Indonesia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 3,582,885

India: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 129,977,615

Ireland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 7,760,048,930

Israel: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 46,327,013

Italy: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 2,704,155,104

Japan: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 1,565,811,607

Korea, Rep.: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 84,311,295

Lithuania: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 3,838,332

Mexico: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 3,570,743

Malta: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 1,522,448

Netherlands: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 709,320,940

Norway: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 24,262,663

New Zealand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 66,749,431

Poland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 32,436,723

Portugal: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 1,479,966

Romania: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 4,789,899

Russian Federation: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 2,318,060

Singapore: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 134,359,683

Slovenia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 11,025,261

Sweden: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 1,841,507,374

Thailand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 10,827,534

Chinese Taipei: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 214,833,803

Uruguay: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 25,034,998

United States: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 6,306,541,184

Vietnam: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 11,204,347

South Africa: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62592 · recorded trade USD 20,950,479

Implementing jurisdiction: China · intervention 62592

Assessment states

Trade-based partners recorded

Measures

Capital grant

Provincial · origin: Chinese firms or production in China · locality: Local firms · CPC 352 · Keyword screen (unreviewed)

Implemented by China (subnational) · affects 45 partners (inferred from trade data, 2023 trade): Ireland, Germany, United States, France, Switzerland, Italy …

对新认定的医药领域全国重点实验室，给予一次性1000万元经费补助；

Supports production in a place, so favours that place by rule.

Full text

各设区市人民政府、赣江新区管委会，各有关单位：现将《江西省支持医药产业高质量发展的若干措施》印发给你们，请抓好贯彻落实。江西省工业强省建设工作领导小组 2024年10月12日（此件主动公开）江西省支持医药产业高质量发展的若干措施为贯彻落实《江西省制造业重点产业链现代化建设“1269”行动计划（2023—2026年）》，促进医药产业高质量发展，经研究，制定如下支持措施。一、支持药械创新研发（一）支持新药及医疗器械研发。充分运用“首席科学家”“揭榜挂帅”“赛马制”等机制，支持医药企业在创新药、高端医疗器械、关键原辅料、新材料等领域开展关键核心技术（产品）攻关，解决“卡脖子”技术难题。对纳入省重点创新产业化升级工程的项目，按相关政策规定每项给予1000-2000万元扶持资金，扶持期限3年，期满后等额收回扶持资金；对纳入省重大科技研发专项的项目，每项给予500-700万元额度支持，原则按照4：3：3比例分年度拨付项目经费；对纳入省重点研发计划的项目，每项按80-120万元给予支持。（责任单位：省科技厅、省发展改革委、省工业和信息化厅、省财政厅、省卫生健康委、省药监局）（二）强化科技创新平台建设。推动中国中医科学院中医药健康产业研究所、经典名方现代中药创制全国重点实验室、重大疾病新药靶发现及新药创制全国重点实验室等国家级科技创新平台建设，推进优化重组后的医药领域省重点实验室建设，以产业急需为导向，加快开展医药领域基础研究和前沿技术研究。对新认定的医药领域全国重点实验室，给予一次性1000万元经费补助；建设期内首次评估验收前，每年对全国重点实验室人才引进、科研仪器设备购置、自主部署课题等予以经费支持，根据绩效情况最高可达1000万元。对优化重组获批的医药领域省重点实验室，给予50万元一次性项目经费补助，后续根据考核评估结果分类支持。对新创建的医药领域国家级、省级制造业创新中心等平台按照500万元和250万元的标准给予一次性补助。支持医学转化研究、细胞生物学组织、基因遗传育种等生命科学领域的新型研发机构发展，推动医药领域省实验室建设。（责任单位：省科技厅、省发展改革委、省工业和信息化厅、省财政厅）（三）强化科技交流合作。深化与中国科学院、中国工程院、中国中医科学院等大院大所合作，积极推动医药产业成果落地。鼓励医药企业在省外创新资源丰富地区设立科创飞地，并可作为参与单位联合本省母公司、高校、科研院所和医疗卫生机构，申报各类科技计划项目，科创飞地人才可作为项目主持人。支持医药领域科创飞地申报江西省重大科技成果熟化与工程化研究项目，引导支持科创飞地成果回赣转化，推荐相关成果纳入江西省现代产业引导基金、江西省科技创新发展基金及其子基金投资项目库，以市场化方式对产业化项目予以支持。（责任单位：省科技厅、省商务厅、省财政厅）二、培育壮大市场主体（四）支持企业壮大升级。鼓励医药生产企业、流通企业整合优势资源，通过兼并整合、收购重组等方式丰富产品管线，完善产业链条，对优化产业链结构的重大并购项目按“一事一议”给予推动。对纳入国家级、省级医药领域专精特新中小企业、制造业单项冠军企业和“独角兽”（潜在、种子）企业、“瞪羚”（潜在）企业的，按规定给予支持。围绕原料药、制剂、炮制、反应器、检测包装等领域，推动全流程监测设备、制剂一体化设备等更新。聚焦各类药物、高端医疗器械、康复辅助器具、高值医用耗材等医药产业链重点发展方向，支持一批制造业重点创新成果产业化项目。支持企业积极融入“一带一路”、粤港澳大湾区等重大战略，引导企业开拓多元化国际市场，帮助企业提升国际化经营能力，鼓励企业参加境外线下展会及赴境外注册商标、申请专利和认证等。（责任单位：省工业和信息化厅、省发展改革委、省科技厅、省财政厅、省商务厅、南昌海关）（五）支持产业数字化转型。支持各设区市对L3级（含）以上医药工业企业开展入企诊断，按规定给予奖补。支持医药企业聚焦全要素、全流程、全生态数字化转型，积极打造“数字领航”医药企业，每家奖励500万元。支持专精特新中小医药企业创建面向行业标杆的“小灯塔”企业，每家奖励100万元。支持医药企业围绕工厂智能化、管理信息化、生产精益化，打造特色鲜明的“数智工厂”，每家奖励100万元。支持以医药产业作为主导产业或优势产业的地方政府在有条件的情况下建设省级“产业大脑”，并按照投入比例给予500万至1000万元奖补。（责任单位：省工业和信息化厅、省财政厅）（六）支持重点产业集群发展。支持产业集群公共服务平台建设，对每年新认定的中小企业公共服务示范平台（基地）给予一次性认定奖励，对获评国家级工业设计中心的给予一次性认定奖励。支持具有创新性、先进性、开放包容性和根植性的医药产业集群申报省级、国家级先进制造业产业集群，对入选的集群给予支持。支持干细胞等未来产业领域科教资源优势突出、产业基础较好的市县开展先导试验区建设，在优势领域打造原始创新策源地和未来产业集群。（责任单位：省工业和信息化厅、省发展改革委、省财政厅）三、优化审评审批流程（七）促进药械审批减时降费提效。医疗器械生产许可办结时限由30个工作日缩减为20个工作日，第二类医疗器械延续注册技术审评时限由60个工作日缩减至30个工作日。药品注册检验时限不超过40个工作日，样品检验和标准复核同时进行的时限不超过60个工作日。继续执行两次各下调药械注册收费标准30%的优惠政策，办理药品上市后变更备案不收取费用。对不属于治疗窗窄的、高活性/高毒性/高致敏性的、生产工艺较难控制的、无菌药品、生物制品，以及特殊管理的药品，其他多个品种陆续变更生产场地的，基于风险原则可按剂型仅对代表性品种开展现场检查。（责任单位：省药监局、省发展改革委、省财政厅）（八）推进注册审评审批改革。为符合国家发展规划和产业政策，具有自主知识产权的重大创新或重大疫情预防治疗需要的疫苗、药品生产企业，在企业注册、生产审批等方面提供绿色通道。优化医联体内医疗机构制剂调剂使用审批流程，支持我省医疗机构制剂按规定调剂使用。开通第二类创新医疗器械审评审批绿色通道，建立审前沟通机制，对列入国家、省级科技重大专项或者国家、省级重点研发计划的项目，优先检验检测、注册核查、审评审批。深入实施医疗器械注册人制度，通过前置咨询、现场指导、专班对接服务我省医疗器械产业发展。对于省内企业受让省外已上市品种的，提前介入，提供服务。对重点品种、临床急需以及重大项目涉及品种的中等变更，在充分保障质量、严格控制风险的前提下，畅通研审联动、备案前沟通交流机制，综合运用合并检查、减少检验、调序提速等措施，加快办理。（责任单位：省药监局）（九）支持上市许可持有人制度实施。鼓励和支持从事药品上市的药学研究机构、药物非临床研究机构、药物临床研究机构、企业研发合同外包服务机构（CRO）等药品研制机构办理药品生产许可证审批，成为药品上市许可持有人。支持省内企业之间通过药品上市许可持有人、医疗器械注册人（备案人）变更，调整产品结构。支持药品生产企业接受上市许可持有人委托生产，允许受托药品生产企业采用拟受托生产的品种（含受托境外生产的品种、受托配置的医疗机构制剂）申请药品GMP检查。（责任单位：省药监局）四、推动药械临床应用（十）加快创新药械临床使用。支持企业参加国家基本医疗保险药品目录谈判，支持中药饮片、中药配方颗粒、医用耗材、医院制剂以及创新医疗技术涉及的医疗服务项目按规定纳入医保目录范围。除国家谈判药品和集中带量采购的药械外，其他药械由企业和医疗机构自主议价，推动建立院内药械配备与医保药械目录调整联动机制，及时优化调整院内药械使用目录。支持对紧密型县域医疗卫生共同体按规定在DRG/DIP政策框架范围内“打包”付费，实行总额包干、结余留用、合理超支分担办法。落实好国谈药品在DRG/DIP支付方式改革中的除外支付政策。指导各统筹区医保部门研究制定新技术、新项目在DRG/DIP支付方式改革中的除外支付政策，健全特例单议制度。推动商业健康保险产品扩大创新药支付范围，探索推进商业健康保险就医费用线上快速结算。（责任单位：省医保局、国家金融监管总局江西监管局）（十一）扩大集采及医保支付范围。及时跟进新批次国家组织药品医用耗材集采，牵头开展一批省级（含省际联盟）药品医用耗材集采，支持将包括赣药赣械在内的更多药械纳入集采范围。对于未纳入集采范围或者集采非中选的赣药赣械，引导其在我省医药集中采购平台挂网，指导医疗机构按需阳光采购。在中医药主管部门确定临床路径和推荐中医优势病种的基础上，开展符合中医药服务特点的支付方式。及时通过医保基金与集采中选医药企业直接结算，保障集采中选企业资金及时回笼,有效解决医药企业“回款难、回款慢”问题，助力企业提速发展。（责任单位：省医保局）（十二）加速促进药械临床研究与转化。鼓励医疗机构取得药物临床试验资质，支持开展江西省临床试验伦理审查互认。依托7个国家区域医疗中心,4个省级区域医疗中心等，构建“3+N”临床试验服务体系，鼓励各中心作为组长单位承接发达地区创新药械的临床试验，力争提高成果转化成功率、缩短临床试验周期、降低企业临床试验成本。加强对医疗机构的评价和激励，着力提升创新医药临床研究质效，加力促进创新医药临床应用，加快集聚创新成果转化。引导医疗机构优化调整床位总量和结构，鼓励提高用于临床研究床位数占医院编制床位总数的比例；加快探索实施对用于临床试验病床可不纳入医院平均住院日、床位周转次数、病床使用率以及相关费用计算等。（责任单位：省卫生健康委、省药监局）五、强化要素保障支撑（十三）加强产业人才引育。支持医药领域院士工作站、博士后工作站建设，对经认定的工作站按规定给予资金支持。着力实施“赣鄱英才计划”，大力引进国内外高端医药人才及团队。畅通医药领域人才职称申报渠道，支持医药领域专业技术人才申报职称，支持医药领域高技能人才申报技能大师工作室。推动校企共建产业学院，增强高层次人才供给，引导企业完善育人机制和留人机制，加大对医药企业职业技能培训补贴力度。（责任单位：省委组织部、省教育厅、省科技厅、省工业和信息化厅、省人力资源社会保障厅）（十四）加大金融支持力度。发挥现有政府投资引导基金作用，带动社会投资，重点扶持科技型、创新型以及具有重大潜在产值贡献的医药企业和重点项目。持续加大信贷投放力度，引导金融机构加大金融产品和服务创新力度，拓宽医药企业融资渠道。对制造业企业技术改造项目贷款、企业设备融资租赁贷款予以贴息，对制造业企业投保的技术创新保险予以保费补偿。支持符合条件的医药企业发行企业债、公司债、资产支持证券等债务融资工具。加大省内医药企业的辅导培育，推动符合条件的医药企业在境内外资本市场上市融资。落实好支持医药产业发展相关税费优惠政策。（责任单位：省地方金融管理局、省工业和信息化厅、省财政厅、省国资委、省税务局、证监会江西监管局、人行江西省分行、国家金融监管总局江西监管局）（十五）强化医药领域质量标准品牌建设。加强医药领域产品全生命周期质量管理，推进中药材GAP示范建设工作。引导医药企业加强全产业链协作，形成设计、制造、使用、售后闭环管理，促进产品质量水平持续提升。支持有条件的单位开展技术标准引进和国际合作，主导和参与制定医药领域相关国际标准、国家标准和行业标准。加强“赣十味”“赣食十味”和地理标志产品品牌建设，持续扩大赣产药材知名度。支持医药生产企业以培育大品种为切入点，实施品牌发展战略，鼓励支持打造一批亿元级大品种。充分运用绿色发展投资贸易博览会、赣商大会、上合组织传统医学论坛、樟树全国药材药品交易会等重大活动平台，全方位宣传提升“赣药赣械”品牌影响力和市场竞争力。（责任单位：省工业和信息化厅、省商务厅、省市场监管局、省药监局、省中医药局）《江西省工业强省建设工作领导小组关于印发江西省支持医药产业高质量发展的若干措施的通知》政策解读